Florian Rambow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7050371/publications.pdf Version: 2024-02-01



FLOPIAN RAMBOW

#	Article	IF	CITATIONS
1	SCENIC: single-cell regulatory network inference and clustering. Nature Methods, 2017, 14, 1083-1086.	9.0	3,086
2	Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell, 2018, 174, 843-855.e19.	13.5	514
3	Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nature Communications, 2015, 6, 6683.	5.8	365
4	Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes and Development, 2019, 33, 1295-1318.	2.7	203
5	Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature, 2018, 558, 605-609.	13.7	177
6	Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma. Nature Cell Biology, 2020, 22, 986-998.	4.6	148
7	Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Nature Communications, 2019, 10, 2723.	5.8	126
8	Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53. Molecular Cell, 2016, 62, 890-902.	4.5	96
9	Mouse Cutaneous Melanoma Induced by Mutant BRaf Arises from Expansion and Dedifferentiation of Mature Pigmented Melanocytes. Cell Stem Cell, 2017, 21, 679-693.e6.	5.2	93
10	Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. Nature Communications, 2018, 9, 2500.	5.8	92
11	Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell, 2021, 39, 1135-1149.e8.	7.7	83
12	A non-coding function of TYRP1 mRNA promotes melanoma growth. Nature Cell Biology, 2017, 19, 1348-1357.	4.6	73
13	Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. Nature Communications, 2018, 9, 4775.	5.8	70
14	Epithelialâ€ŧoâ€mesenchymalâ€like transition events in melanoma. FEBS Journal, 2022, 289, 1352-1368.	2.2	54
15	A stromal Integrated Stress Response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression. Nature Cell Biology, 2022, 24, 940-953.	4.6	52
16	The long noncoding RNA <i>NEAT1_1</i> is seemingly dispensable for normal tissue homeostasis and cancer cell growth. Rna, 2019, 25, 1681-1695.	1.6	39
17	Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma. Oncotarget, 2016, 7, 71873-71886.	0.8	35
18	Dynamic reversal of random X-Chromosome inactivation during iPSC reprogramming. Genome Research, 2019, 29, 1659-1672.	2.4	31

FLORIAN RAMBOW

#	Article	IF	CITATIONS
19	Disseminated Melanoma Cells Transdifferentiate into Endothelial Cells in Intravascular Niches at Metastatic Sites. Cell Reports, 2020, 31, 107765.	2.9	26
20	Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma. Journal of Clinical Investigation, 2017, 127, 2310-2325.	3.9	26
21	Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas. Molecular Cancer Therapeutics, 2019, 18, 289-300.	1.9	25
22	CRISPR screens identify tumorâ€promoting genes conferring melanoma cell plasticity and resistance. EMBO Molecular Medicine, 2021, 13, e13466.	3.3	16
23	Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value. Frontiers in Oncology, 2021, 11, 780654.	1.3	7